Piotr
Wrzosinski
I design and lead commercial transformation in life sciences, building the operating models that make AI, omnichannel, and market execution work at scale.
Current focus: BD EMEA commercial transformation infrastructure across 30+ markets, connecting platform strategy, governance, content, customer engagement, and execution in regulated environments. Earlier roles at Roche, Janssen/J&J, Pfizer, Accenture, and IQVIA gave me the cross-sector depth to see where transformation holds — and where it quietly breaks.
“Transformation rarely fails because the ambition is too small. It fails because the operating model doesn’t hold.”
Piotr Wrzosinski
Strategy that becomes structure.
Structure that becomes scale.
A life sciences commercial transformation profile built across pharma, MedTech, digital health, and consulting — with enough operating depth to make change real and enough strategic range to make it last.
My work sits where commercial strategy, operating model design, and enterprise execution converge. The constant thread is not channels or campaigns. It is building the structures that let organisations scale customer engagement, AI, governance, and capability without losing coherence across markets.
Across BD, Roche, Janssen/J&J, Pfizer, Accenture, and IQVIA, I have worked on the practical mechanics of commercial change in regulated industries: how you move from ambition to operating model, from technology selection to adoption, and from isolated pilots to something the business can actually scale.
That means turning transformation into the things organisations actually need: governance that holds, role design that is workable, platform choices that fit the model, and commercial systems that still make sense once the initial push is over.
Today at BD, I lead a cross-border team building the governance, platforms, customer-engagement models and commercial capabilities that support transformation across EMEA.
Operating across markets, teams and sectors
A concise view of the scale and organisational complexity behind the work.
Signature domains
The areas where I create the most value are connected parts of the same challenge: how life sciences organisations redesign commercial work for scale, complexity, and the AI era.
Commercial transformation in life sciences
Designing transformation from strategic intent through operating model, governance, and market execution — built to hold in regulated, matrixed, enterprise environments.
Enterprise StrategyAI-enabled operating models
Using AI where it changes the operating layer, not just the tooling — governance, decision rights, content models, customer engagement logic, and the structure required to move beyond disconnected pilots.
AI & GovernanceGovernance, platform strategy & transformation design
Building governance frameworks, role models, and platform strategies that support transformation at scale — and stop organisations buying technology before they know what model it needs to serve.
Operating Model DesignOmnichannel & customer engagement at scale
Designing customer engagement models that connect content, channels, data, and commercial priorities — not as campaign mechanics, but as part of the enterprise commercial operating model.
Customer EngagementMedical-commercial alignment
Closing one of the most expensive gaps in life sciences transformation: the structural disconnect between medical credibility, commercial priorities, data models, and the decisions organisations expect teams to share.
Cross-Functional DesignTransformation that survives handover
The standard I care about most: whether the model still works when the transformation leader is no longer in the room. Durable change depends on governance, documentation, capability, and adoption — not charisma.
Durability of ChangePractitioner-led thinking
I write at disrupting.healthcare about commercial transformation, operating-model redesign, MedTech, regulation, and what AI actually changes in life sciences once the pilot theatre ends.
European Life Sciences Commercial Transformation: What H1 2026 Actually Changed
Why advantage is moving beyond the product towards the institutional capability required to convert science into approval, adoption and scale.
Read the analysisAI-Powered Commercial Operating Models in Life Sciences
AI adoption is not operating-model redesign. Decision rights, governance, data and roles must change before commercial AI can scale.
Read the analysisEurope Life Sciences Weekly Signal #49: The Operating Model Gets Priced
Markets distinguished assets from systems: a premium for conversion capacity, and a discount for friction at the interfaces.
Read the latest SignalOpen to the right conversations
I welcome conversations with life-sciences leaders working through commercial transformation, AI-enabled operating models, cross-market governance and European market execution.
piotr@wrzosinski.com